Journal of Tissue Viability
Volume 17, Issue 4 , Pages 115-120 , November 2008

Risk assessment for prevention of morbidity and mortality: Lessons for pressure ulcer prevention

  • T.M. Reynolds

      Affiliations

    • Department of Clinical Chemistry, Queen's Hospital, Burton-upon-Trent, UK
    • Division of Sciences, Wolverhampton University, UK
    • Corresponding Author InformationDepartment of Clinical Chemistry, Queen's Hospital, Belvedere Road, Burton-upon-Trent, Staffordshire DE13 0RB, UK. Tel.: +44 (0)1283 511511x4035; fax: +44 (0)1283 593064.

References 

  1. Fontana RS, Sanderson DR, Woolner LB, Taylor WF, Miller WE, Muhm JR, et al. Screening for lung cancer. A critique of the Mayo Lung Project. Cancer. 1991;67(Suppl. 4):1155–1164
  2. Tannock IF. Eradication of a disease: how we cured asymptomatic prostate cancer. Lancet Oncol. 2000 May;17–18
  3. JBS2 . Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(Suppl. 5):1–52
  4. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293–298
  5. Reynolds TM, Twomey P, Wierzbicki AS. Accuracy of cardiovascular risk estimation for primary prevention in patients without diabetes. J Cardiovasc Risk. 2002;9:183–190
  6. Wierzbicki A, Reynolds T, Gill K, Alg S, Crook M. A comparison of algorithms for initiation of lipid lowering therapy in primary prevention of coronary heart disease. J Cardiovasc Risk. 2000;7:63–73
  7. Reynolds TM, Twomey P, Wierzbicki AS. Concordance evaluation of the coronary risk scores: implications for CHD risk screening. Curr Med Res Opin. 2004;20:811–818
  8. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular event. N Engl J Med. 2002;347:1557–1565
  9. Wilson PF, Nam B-H, Pencina M, D'Agostino R, Benjamin EJ, O'Donnell CJ. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham study. Arch Intern Med. 2005;165:2473–2478
  10. Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers. Arch Intern Med. 2006;166:1368–1373
  11. Kumana CR, Cheung BMY, Lauder IJ. Gauging the impact of statins using number needed to treat. J Am Med Assoc. 1999;282:1899–1901
  12. Oliver SE, Gunnel D, Donovan JL. Comparison of trends in prostate cancer mortality in England and Wales and the USA. Lancet. 2000;355:1788–1789
  13. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. Br Med J. 2002;325:740–745
  14. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng/milliliter. N Engl J Med. 2004;350:2239–2246
  15. Higashihara E, Nutahara K, Kojima M, Okegawa T, Miura I, Miyata A, et al. Significance of serum free prostate specific antigen in the screening of prostate cancer. J Urol. 1996;156:1964–1968
  16. Reynolds T, Penney M. The mathematical basis of multivariate risk analysis: with special reference to screening for Down's syndrome associated pregnancy. Ann. Clin. Biochem. 1990;27:452–458
  17. Reynolds T. Down's syndrome screening is unethical: views of today's ethics committees. J Clin Pathol. 2003;56:268–270
  18. Wald N, Cuckle H, Densem J, Nanchahal K, Royston P, Chard T, et al. Maternal serum screening for Down's syndrome in early pregnancy. Br Med J. 1988;297:883–887
  19. Reynolds T, John R, Spencer K. The use of unconjugated estriol in Down syndrome screening is unproven. Clin Chem. 1993;39:2023–2025
  20. Wilson JM, Jungner G. Principles and practice of screening for disease. Geneva: World Health Organisation; 1968;Public Health Paper Number 34
  21. Carter HB. Prostate cancer in men with low PSA levels – must we find them?. N Engl J Med. 2004;350:2292–2294
  22. Anthony D, Reynolds T, Russell L. The role of hospital-acquired pressure ulcer in length of stay. Clin Eff Nurs. 2004;8:4–10
  23. Grey JE, Enoch S, Harding KG. ABC of wound healing: pressure ulcers. Br Med J. 2006;332:472–475
  24. Russell LJ, Reynolds TM, Park C, Rithalia S, Gonsalkorale M, Birch J, et al. Randomized clinical trial comparing 2 support surfaces: results of the prevention of pressure ulcers study. Adv Skin Wound Care. 2003;16:317–327
  25. Nixon J, Cranny G, Iglesias C, Nelson A, Hawkins K, Phillips A, et al. Randomised controlled trial of alternating pressure mattresses compared with alternating pressure overlays for the prevention of pressure ulcers: PRESSURE (pressure relieving support surfaces) trial. Br Med J. 2006;332:1413–1415
  26. Russell L, Reynolds T, Towns A, Worth W, Greenman A, Turner R. Randomized comparison trial of the RIK and Nimbus 3 mattresses. Br J Nurs. 2003;12:254–259
  27. National Institute for Clinical Excellence . Inherited clinical guidance B: pressure ulcer risk assessment and prevention. London: NICE; 2001;
  28. Schoonhoven L, Haalboom JRE, Bousema MT, Algra A, Grobbee DE, Grypdonck MH, et al. Prospective cohort study of routine use of risk assessment scales for prevention of pressure ulcers. Br Med J. 2002;325:797–801
  29. Anthony D, Reynolds T, Russell L. A regression analysis of the Waterlow score in pressure ulcer risk assessment. Clin Rehabil. 2003;17:216–233
  30. Anthony D, Russell L, Reynolds T. An investigation into the use of serum albumin in pressure sore prediction. J Adv Nurs. 2000;32:359–365
  31. Reynolds TM, Stokes A, Russell L. Assessment of a prognostic biochemical indicator of nutrition and inflammation for identification of pressure ulcer risk. J Clin Path. 2006;59:308–310
  32. Ingenbleek Y, Carpentier YA. A prognostic inflammatory and nutritional index scoring critically ill patients. Int J Vitam Nutr Res. 1985;55:91–101
  33. Perier C, Granouillet R, Chamson A, Gonthier R, Frey J. Nutritional markers, acute phase reactants and tissue inhibitor of matrix metalloproteinase I in elderly patients with pressure sores. Gerontology. 2002;48:298–301

PII: S0268-0009(07)00013-3

doi: 10.1016/j.jtv.2007.09.005

Journal of Tissue Viability
Volume 17, Issue 4 , Pages 115-120 , November 2008

Article Tools